| Title |
The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, January 2012
|
| DOI | 10.1007/s00280-012-1828-8 |
| Pubmed ID | |
| Authors |
Ye-min Wang, Bao-zhe Jin, Fang Ai, Chang-hong Duan, Yi-zhong Lu, Ting-fang Dong, Qing-lin Fu |
| Abstract |
Recently, melatonin has been associated with cancer both in vitro and in vivo. However, the value of melatonin in the treatment of cancer remains disputable. Hence, we performed a systematic review of randomized controlled trials (RCTs) of melatonin in solid tumor cancer patients and observed its effect on tumor remission, 1-year survival, and side effects due to radiochemotherapy. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 3 | 30% |
| United States | 1 | 10% |
| Canada | 1 | 10% |
| Unknown | 5 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 70% |
| Practitioners (doctors, other healthcare professionals) | 2 | 20% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 135 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 4% |
| Spain | 1 | <1% |
| Canada | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 127 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 17 | 13% |
| Other | 16 | 12% |
| Researcher | 15 | 11% |
| Student > Doctoral Student | 14 | 10% |
| Student > Master | 13 | 10% |
| Other | 24 | 18% |
| Unknown | 36 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 56 | 41% |
| Agricultural and Biological Sciences | 11 | 8% |
| Biochemistry, Genetics and Molecular Biology | 8 | 6% |
| Nursing and Health Professions | 6 | 4% |
| Psychology | 6 | 4% |
| Other | 12 | 9% |
| Unknown | 36 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2023.
All research outputs
#1,406,281
of 24,088,850 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#25
of 2,512 outputs
Outputs of similar age
#9,901
of 252,957 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#1
of 19 outputs
Altmetric has tracked 24,088,850 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,512 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 252,957 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.